Table 1.
Baseline patient and treatment characteristics
| Characteristics | n=30 |
|---|---|
| Median age, years (IQR) | 51.5 (47–55) |
| Gender | |
| Female | 11 |
| Male | 19 |
| Race | |
| White | 25 |
| Non-white | 5 |
| T stage* | |
| 2 | 3 |
| 3 | 22 |
| 4 | 4 |
| Unknown^ | 1 |
| N stage* | |
| 0 | 18 |
| 1 | 5 |
| X | 6 |
| Unknown^ | 1 |
| M stage* | |
| 0 | 17 |
| 1 | 12 |
| Unknown^ | 1 |
| Grade | |
| 1 | 2 |
| 2 | 2 |
| 3 | 12 |
| 4 | 15 |
| Prior systemic therapy | 6 |
| Number of lesions | |
| <4 | 5 |
| 4–10 | 17 |
| >10 | 8 |
| Heng score | |
| 0 | 12 |
| 1 | 9 |
| 2 | 8 |
| 3 | 1 |
| Motzer score | |
| 0 | 11 |
| 1 | 8 |
| 2 | 7 |
| 3 | 3 |
| unknown | 1 |
| Median β2 microglobulin (IQR) | 2.89 (2.60–3.33) |
| Number of sites treated | |
| 1 | 14 |
| 2 | 15 |
| 3 | 1 |
| Sites treated with SAbR | |
| Lung | 21 |
| Bone | 8 |
| Liver | 2 |
| IL-2 Courses | |
| 1 | 18 |
| 2 | 9 |
| 3 | 3 |
| IL-2 Cycles | |
| 1 | 3 |
| 2 | 15 |
| 3 | 1 |
| 4+ | 11 |
| Median IL-2 doses (IQR) | 17.5 (13.25–28.75) |
IQR, interquartile range; SAbR, stereotactic ablative body radiotherapy;
IL-2, interleukin-2
*
Staging at initial diagnosis of RCC
^
Record was not available